Pancreatic cancer patients in Ukraine treated with TSE continues to have a good quality of life

Scandinavian ChemoTech has received encouraging updated information from Ulis Hospital Ukraine, which states that the performance status of the treated pancreatic cancer patients continues to be good close to six months after treatment.

The two unresectable pancreatic cancer patients at Ulis Hospital in Ukraine who received TSE treatments in combination with a low dose of chemotherapy, using ChemoTech’s IQwave™ device six months back, continue to have a good quality of life with an ECOG score of 1, and are not on any pain relief medication. Both patients are restricted from physically strenuous activity, but they are ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. The ‘Eastern Cooperative Oncology Group’ (ECOG) score is a prognostic and Performance Status Scale widely used to assess the functional status of a patient.1

It is pertinent to mention that the post-treatment CT scans of the two patients had shown almost a 50% decrease in tumour mass.

More patients are in line for treatment at Ulis Hospital. After seeing the promising results in Ukraine there is now an international study being planned of TSE in combination with immunotherapy.

“Six months is a major landmark for advanced pancreatic cancer and our patients continue to do well. We are of the opinion that the TSE technology has made a major impact on primary tumour reduction in these two patients who could not be taken for surgery.   Prevention of metastatic progression will require combinations of TSE to be explored.  We would again like to appeal to cancer researchers internationally to join hands with us in our pursuit of exploring the TSE technology further, possibly in combination with immune-oncology drugs. ”- says Professor Alexei Kovalev Ulis Hospital.

“Looking at the treatment response so far, we are optimistic of a favourable survival for these patients. This is a major efficacy signal for TSE technology, and we are moving ahead with an international study for pancreaticobiliary cancers.” - says Dr Suhail Mufti, Medical Director at Scandinavian ChemoTech.

The global pancreatic cancer market is valued at around US$ 2,125.57 Million in 2023. This market is furthermore expected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033.2

About Tumour Specific Electroporation™ - TSE

TSE is a patented tumour-specific technology that is developed to improve the uptake of low doses of chemotherapy with at least 1000 times higher infiltration. The TSE adapts the electrical field to avoid unwanted destruction of both cancerous and healthy tissue. It has been shown to reduce necrosis and tissue damage, as well as change the cellular characteristics in the tumours to be eligible for immune responses.

The pancreatic cancer cases in Ukraine were performed under open surgery in combination with a very low dose of Bleomycin. ChemoTech’s target for the next 2–3 years is to combine TSE with a laparoscopic or robotic solution to enable to treat deep-seated tumours multiple times.

1Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-655. PMID: 7165009. https://ecog-acrin.org/resources/ecog-performance-status/

2https://www.futuremarketinsights.com/reports/pancreatic-cancer-market

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.